Glenmark Pharma files application of human trial in Netherlands for GRC 17536 molecule
17 Feb 2011
According to drug maker, Glenmark Pharmaceuticals it has filed an application for human trials in Netherlands for its molecule 'GRC 17536', which is aimed to treat pain and respiratory disorders.
In a filing to the Bombay Stock Exchange, the company said it had completed animal trials on its novel chemical entity (NCE)-GRC 17536 and has filed the Phase I application for the first-in-man trial in Netherlands.
Glenmark Pharmaceuticals CEO and MD Glenn Saldanha said the company was excited that its Transient Receptor Potential Antagonist (TRPA)1 discovery programme was moving forward to human trials. He added this was another potential first-in-class molecule indicated for both pain and respiratory conditions.
According to the company, the total market for asthma and chronic lung disease was nearly $30 billion and for osteoarthritis and neuropathic pain around $10 billion.
He added there was a huge unmet medical demand for both therapeutic areas globally. He said GRC 17536 was highly selective even when compared with other (Transient Receptor Potential) TRPs and could be administered orally.
At this point, the drug would enter phase I of human trails to be conducted on a set of healthy volunteers in Europe. Phase II trials would be proof of concept post the phase I human trails.